How to buy Taysha Gene Therapies stock (Taysha Gene Therapies)

Taysha Gene Therapies is a biotechnology business based in the US. Taysha Gene Therapies shares (TSHA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.85 – a decrease of 10.63% over the previous week. Taysha Gene Therapies employs 52 staff and has a trailing 12-month revenue of around $9.9 million.

Our top picks for where to buy Taysha Gene Therapies Inc stock

Buy Taysha Gene Therapies stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Taysha Gene Therapies stock price (NASDAQ: TSHA)

Use our graph to track the performance of TSHA stocks over time.

Taysha Gene Therapies shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.85
52-week range	$1.19 - $4.32
50-day moving average more info button	$2.13
200-day moving average more info button	$2.44
Wall St. target price	$6.59
PE ratio more info button	2.9048
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.63

Is it a good time to buy Taysha Gene Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Taysha Gene Therapies price performance over time

Historical closes compared with the close of $1.85 from 2024-12-20

1 week (2024-12-13)	-10.63%
1 month (2024-11-22)	-25.10%
3 months (2024-09-20)	-13.95%
6 months (2024-06-21)	-37.50%

1 year (2023-12-22)	13.50%
2 years (2022-12-22)	-7.04%
3 years (2021-12-22)	13.17
5 years (2019-12-18)	N/A

Is Taysha Gene Therapies stock undervalued or overvalued?

Valuing Taysha Gene Therapies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Taysha Gene Therapies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Taysha Gene Therapies's P/E ratio

Taysha Gene Therapies's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Taysha Gene Therapies shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Taysha Gene Therapies's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• Uniqure (QURE.US): 0.00
• Voyager Therapeutics (VYGR.US): 8.77
• Inovio Pharmaceuticals (INO.US): 0.00

Taysha Gene Therapies financials

Revenue TTM	$9.9 million
Gross profit TTM	$2.5 million
Return on assets TTM	-27.42%
Return on equity TTM	-114.77%
Profit margin	-229.67%
Book value	$0.33
Market Capitalization more info button	$375 million

TTM: trailing 12 months

Taysha Gene Therapies share dividends

We're not expecting Taysha Gene Therapies to pay a dividend over the next 12 months.

You may also wish to consider:

Taysha Gene Therapies share price volatility

Over the last 12 months, Taysha Gene Therapies's shares have ranged in value from as little as $1.19 up to $4.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Taysha Gene Therapies's is 0.414. This would suggest that Taysha Gene Therapies's shares are less volatile than average (for this exchange).

To put Taysha Gene Therapies's beta into context you can compare it against those of similar companies.

• Uniqure (QURE.US): 0.902
• Voyager Therapeutics (VYGR.US): 0.889
• Inovio Pharmaceuticals (INO.US): 0.833

Taysha Gene Therapies overview

Taysha Gene Therapies, Inc. , a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Frequently asked questions

What percentage of Taysha Gene Therapies is owned by insiders or institutions?
Currently 17.538% of Taysha Gene Therapies shares are held by insiders and 77.156% by institutions. How many people work for Taysha Gene Therapies?
Latest data suggests 52 work at Taysha Gene Therapies. When does the fiscal year end for Taysha Gene Therapies?
Taysha Gene Therapies's fiscal year ends in December. Where is Taysha Gene Therapies based?
Taysha Gene Therapies's address is: 3000 Pegasus Park Drive, Dallas, TX, United States, 75247 What is Taysha Gene Therapies's ISIN number?
Taysha Gene Therapies's international securities identification number is: US8776191061